ArticleNature communications2014
NAD+ protects against EAE by regulating CD4+ T-cell differentiation.
Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines.International journal of molecular sciences · 2020Pooled it
- NAMPT activity plays a key role in driving autoimmune processes that mediate beta-cell death and type 1 diabetes development in mice.Cell death & disease · 2026Article
- Vascular Immune Remodeling: A CD4Aging cell · 2026Article
- Glomerular endothelial cells eliminate nicotinamide adenine dinucleotide to instruct CD103Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Immunometabolism in heart failure.Nature reviews. Cardiology · 2025Review
- Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure.Nature cancer · 2025Article
- NAD + metabolism and function in innate and adaptive immune cells.Journal of inflammation (London, England) · 2025Review
- Nicotinamide Adenine Dinucleotide Supplementation Improves Cuprizone-Induced Multiple Sclerosis-Related Behavioral Changes in C57BL/6J Mice.Brain and behavior · 2025Article
- PPDPF preserves integrity of proximal tubule by modulating NMNAT activity in chronic kidney diseases.Science advances · 2025Article
- Article
- Article
- Multicenter Validation of lncRNA and Target mRNA Diagnostic and Prognostic Biomarkers of Acute Ischemic Stroke From Peripheral Blood Leukocytes.Journal of the American Heart Association · 2024Article
- Targeting NAD+ Metabolism to Modulate Autoimmunity and Inflammation.Journal of immunology (Baltimore, Md. : 1950) · 2024Review
- A microbially produced AhR ligand promotes a Tph1-driven tolerogenic program in multiple sclerosis.Scientific reports · 2024Article
- NADeLife · 2024Article
- Impact of NAD+ metabolism on ovarian aging.Immunity & ageing : I & A · 2023Review
- Effect of β-Nicotinamide Adenine Dinucleotide on Acute Allograft Rejection After Rat Lung Transplantation.Transplantation direct · 2023Article
- Implications of immunometabolism for smouldering MS pathology and therapy.Nature reviews. Neurology · 2023Review
- NADCell & bioscience · 2023Review
- Metabolic dysregulation impairs lymphocyte function during severe SARS-CoV-2 infection.Communications biology · 2023Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 7 institutions in 2 countries.
Funding
Abstract
CD4(+) T cells are involved in the development of autoimmunity, including multiple sclerosis (MS). Here we show that nicotinamide adenine dinucleotide (NAD(+)) blocks experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, by inducing immune homeostasis through CD4(+)IFNγ(+)IL-10(+) T cells and reverses disease progression by restoring tissue integrity via remyelination and neuroregeneration. We show that NAD(+) regulates CD4(+) T-cell differentiation through tryptophan hydroxylase-1 (Tph1), independently of well-established transcription factors. In the presence of NAD(+), the frequency of T-bet(-/-) CD4(+)IFNγ(+) T cells was twofold higher than wild-type CD4(+) T cells cultured in conventional T helper 1 polarizing conditions. Our findings unravel a new pathway orchestrating CD4(+) T-cell differentiation and demonstrate that NAD(+) may serve as a powerful therapeutic agent for the treatment of autoimmune and other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.